Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $4.98
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 24, 26 | Roth Capital |
| maintain |
| Buy |
| Buy |
| Aug 20, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Jun 8, 26 | Ascendiant Capital | maintain | Buy | Buy |
| May 26, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 8, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Mar 23, 26 | Roth Capital | maintain | Buy | Buy |
| Dec 8, 25 | Ascendiant Capital | maintain | Buy | Buy |
| Nov 19, 25 | Roth Capital | maintain | Buy | Buy |
| Oct 15, 25 | Roth Capital | maintain | Buy | Buy |
1224 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 57.28 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 73.48 | Oscillator | Neutral |
| Williams %R (14) | -2.27 | Oscillator | Sell |
| MACD (12, 26, 9) | -0.10 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 27.13 (+DI 18.8 / -DI 21.4) | Trend | Strong Sell |
| EMA 20 | 4.74 | MA | Strong Buy |
| SMA 20 | 4.73 | MA | Strong Buy |
| EMA 50 | 4.89 | MA | Buy |
| SMA 50 | 5.03 | MA | Sell |
| SMA 200 | 5.43 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | CING | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.0x | -4.3x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.3x | EPS est. -2.13 | Elevated |
| Price / Book | 1.2x | 22.8x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -2.0x | -15.5x | Discount |
| Return on equity | -238.4% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.27 | 1.05 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -3.67 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Silva Raul R. | officer: EVP and CSO | A-Award | 4,293 @ $4.95 | $21.25K |
Stock news · updated daily
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.
| Jul 16, 26 |
| Schaffer Shane J. |
| director, officer: Chief Executive Officer |
| A-Award |
| 197,650 @ $4.43 |
| $875.6K |
| Jul 16, 26 | Schaffer Shane J. | director, officer: Chief Executive Officer | A-Award | 97,350 @ $4.43 | $431.3K |
| Jul 16, 26 | Downey Bryan Wade | officer: EVP & Chief Commercial Officer | A-Award | 67,000 @ $4.43 | $296.8K |
| Jul 16, 26 | Downey Bryan Wade | officer: EVP & Chief Commercial Officer | A-Award | 33,000 @ $4.43 | $146.2K |
| Jul 16, 26 | Lawrence Bryan Jay | director | A-Award | 20,000 @ $4.43 | $88.60K |
| Jul 16, 26 | Brams Matthew | officer: EVP and Chief Medical Officer | A-Award | 53,600 @ $4.43 | $237.4K |
| Jul 16, 26 | Brams Matthew | officer: EVP and Chief Medical Officer | A-Award | 26,400 @ $4.43 | $117.0K |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.63 | -0.45 | Beat 28.0% | — |
| May 14, 2026 | -0.53 | -0.95 | Miss -79.2% | — |
| Mar 18, 2026 | -0.56 | -0.84 | Miss -50.0% | — |
| Nov 13, 2025 | -0.80 | -1.35 | Miss -68.8% | — |
| Aug 19, 2025 | -0.82 | -1.09 | Miss -32.9% | — |
| May 8, 2025 | -1.00 | -1.04 | Miss -4.0% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 2, 2026 | 2026-10-02 17:00:38 | View |
| 8-K | Oct 2, 2026 | 2026-10-02 16:30:32 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 08:45:38 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 08:40:15 | View |
| 8-K | Jul 23, 2026 | 2026-07-23 16:05:32 | View |
| 4 | Jul 20, 2026 | 2026-07-20 19:37:49 | View |
| 4 | Jul 20, 2026 | 2026-07-20 19:35:39 | View |
| 4 | Jul 20, 2026 | 2026-07-20 19:32:30 | View |
| 4 | Jul 20, 2026 | 2026-07-20 19:32:12 | View |
| 4 | Jul 20, 2026 | 2026-07-20 19:29:57 | View |
Proxy statement (DEF 14A) disclosures